ID   KS6A4_HUMAN             Reviewed;         772 AA.
AC   O75676; A8K7Z8; O75585; Q53ES8;
DT   24-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   12-OCT-2022, entry version 203.
DE   RecName: Full=Ribosomal protein S6 kinase alpha-4;
DE            Short=S6K-alpha-4;
DE            EC=2.7.11.1;
DE   AltName: Full=90 kDa ribosomal protein S6 kinase 4;
DE   AltName: Full=Nuclear mitogen- and stress-activated protein kinase 2;
DE   AltName: Full=Ribosomal protein kinase B;
DE            Short=RSKB;
GN   Name=RPS6KA4; Synonyms=MSK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000312|EMBL:CAA09009.1};
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, ACTIVITY REGULATION,
RP   INTERACTION WITH MAPK14; MAPK1 AND MAPK3, AND SUBCELLULAR LOCATION.
RC   TISSUE=Placenta {ECO:0000312|EMBL:CAA09009.1};
RX   PubMed=9792677; DOI=10.1074/jbc.273.45.29661;
RA   Pierrat B., Correia J.D.S., Mary J.L., Tomas-Zuber M., Lesslauer W.;
RT   "RSK-B, a novel ribosomal S6 kinase family member, is a CREB kinase under
RT   dominant control of p38alpha mitogen-activated protein kinase
RT   (p38alphaMAPK).";
RL   J. Biol. Chem. 273:29661-29671(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Synovium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT ALA-758.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 17-727 (ISOFORM 2).
RX   PubMed=9687510; DOI=10.1093/emboj/17.15.4426;
RA   Deak M., Clifton A.D., Lucocq J.M., Alessi D.R.;
RT   "Mitogen- and stress-activated protein kinase-1 (MSK1) is directly
RT   activated by MAPK and SAPK2/p38, and may mediate activation of CREB.";
RL   EMBO J. 17:4426-4441(1998).
RN   [6]
RP   FUNCTION, INTERACTION WITH MAPK14, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   PHE-709.
RX   PubMed=11035004; DOI=10.1074/jbc.m005822200;
RA   Tomas-Zuber M., Mary J.L., Lamour F., Bur D., Lesslauer W.;
RT   "C-terminal elements control location, activation threshold, and p38
RT   docking of ribosomal S6 kinase B (RSKB).";
RL   J. Biol. Chem. 276:5892-5899(2001).
RN   [7]
RP   FUNCTION IN PHOSPHORYLATION OF HISTONE H3 AND HMGN1/HMG14.
RX   PubMed=12773393; DOI=10.1093/emboj/cdg273;
RA   Soloaga A., Thomson S., Wiggin G.R., Rampersaud N., Dyson M.H.,
RA   Hazzalin C.A., Mahadevan L.C., Arthur J.S.;
RT   "MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of
RT   histone H3 and HMG-14.";
RL   EMBO J. 22:2788-2797(2003).
RN   [8]
RP   REVIEW ON FUNCTION.
RX   PubMed=18508628; DOI=10.2741/3122;
RA   Arthur J.S.;
RT   "MSK activation and physiological roles.";
RL   Front. Biosci. 13:5866-5879(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-347; SER-634; SER-678;
RP   THR-687 AND SER-745, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-347; THR-542 AND THR-687, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [12]
RP   REVIEW ON FUNCTION.
RX   PubMed=19464896; DOI=10.1016/j.tibs.2009.02.007;
RA   Vermeulen L., Vanden Berghe W., Beck I.M., De Bosscher K., Haegeman G.;
RT   "The versatile role of MSKs in transcriptional regulation.";
RL   Trends Biochem. Sci. 34:311-318(2009).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-347; THR-542 AND THR-687, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-678 AND SER-745, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-236 AND ALA-758.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that is required for the
CC       mitogen or stress-induced phosphorylation of the transcription factors
CC       CREB1 and ATF1 and for the regulation of the transcription factor RELA,
CC       and that contributes to gene activation by histone phosphorylation and
CC       functions in the regulation of inflammatory genes. Phosphorylates CREB1
CC       and ATF1 in response to mitogenic or stress stimuli such as UV-C
CC       irradiation, epidermal growth factor (EGF) and anisomycin. Plays an
CC       essential role in the control of RELA transcriptional activity in
CC       response to TNF. Phosphorylates 'Ser-10' of histone H3 in response to
CC       mitogenics, stress stimuli and EGF, which results in the
CC       transcriptional activation of several immediate early genes, including
CC       proto-oncogenes c-fos/FOS and c-jun/JUN. May also phosphorylate 'Ser-
CC       28' of histone H3. Mediates the mitogen- and stress-induced
CC       phosphorylation of high mobility group protein 1 (HMGN1/HMG14). In
CC       lipopolysaccharide-stimulated primary macrophages, acts downstream of
CC       the Toll-like receptor TLR4 to limit the production of pro-inflammatory
CC       cytokines. Functions probably by inducing transcription of the MAP
CC       kinase phosphatase DUSP1 and the anti-inflammatory cytokine interleukin
CC       10 (IL10), via CREB1 and ATF1 transcription factors.
CC       {ECO:0000269|PubMed:11035004, ECO:0000269|PubMed:12773393,
CC       ECO:0000269|PubMed:9792677}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:9792677};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:9792677};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:9792677};
CC   -!- ACTIVITY REGULATION: Activated by phosphorylation at Ser-343, Thr-568
CC       and Thr-687 by MAPK1/ERK2, MAPK3/ERK1 and MAPK14/p38-alpha, and by
CC       further autophosphorylation of Ser-196, Ser-360 and Ser-365 by the
CC       activated C-terminal kinase domain. {ECO:0000250}.
CC   -!- SUBUNIT: Forms a complex with either MAPK1/ERK2 or MAPK3/ERK1 in
CC       quiescent cells which transiently dissociates following mitogenic
CC       stimulation. Also associates with MAPK14/p38-alpha. Activated RPS6KA4
CC       associates with and phosphorylates the NF-kappa-B p65 subunit RELA.
CC   -!- INTERACTION:
CC       O75676; Q16539: MAPK14; NbExp=6; IntAct=EBI-73933, EBI-73946;
CC       O75676-2; O14901: KLF11; NbExp=3; IntAct=EBI-21622593, EBI-948266;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11035004,
CC       ECO:0000269|PubMed:9792677}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O75676-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O75676-2; Sequence=VSP_017733;
CC   -!- PTM: Ser-343 and Thr-568 phosphorylation is required for kinase
CC       activity. Ser-343 and Ser-196 are autophosphorylated by the C-terminal
CC       kinase domain, and their phosphorylation is essential for the catalytic
CC       activity of the N-terminal kinase domain. Phosphorylated at Ser-343,
CC       Thr-568 and Thr-687 by MAPK1/ERK2, MAPK3/ERK1 and MAPK14/p38-alpha.
CC       Autophosphorylated at Ser-737 and Ser-745 by the N-terminal kinase
CC       domain (By similarity). {ECO:0000250}.
CC   -!- MISCELLANEOUS: Enzyme activity requires the presence of both kinase
CC       domains. {ECO:0000250|UniProtKB:O75582}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. S6 kinase subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ010119; CAA09009.1; -; mRNA.
DR   EMBL; AK223561; BAD97281.1; -; mRNA.
DR   EMBL; AK292163; BAF84852.1; -; mRNA.
DR   EMBL; CH471076; EAW74260.1; -; Genomic_DNA.
DR   EMBL; AF074715; AAC67395.1; -; mRNA.
DR   CCDS; CCDS8073.1; -. [O75676-1]
DR   RefSeq; NP_001006945.1; NM_001006944.1. [O75676-2]
DR   RefSeq; NP_001287731.1; NM_001300802.1.
DR   RefSeq; NP_001305290.1; NM_001318361.1.
DR   RefSeq; NP_003933.1; NM_003942.2. [O75676-1]
DR   AlphaFoldDB; O75676; -.
DR   SMR; O75676; -.
DR   BioGRID; 114468; 102.
DR   ELM; O75676; -.
DR   IntAct; O75676; 24.
DR   MINT; O75676; -.
DR   STRING; 9606.ENSP00000333896; -.
DR   BindingDB; O75676; -.
DR   ChEMBL; CHEMBL3125; -.
DR   DrugBank; DB03247; Flavin mononucleotide.
DR   DrugCentral; O75676; -.
DR   GuidetoPHARMACOLOGY; 1524; -.
DR   GlyGen; O75676; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; O75676; -.
DR   PhosphoSitePlus; O75676; -.
DR   BioMuta; RPS6KA4; -.
DR   EPD; O75676; -.
DR   jPOST; O75676; -.
DR   MassIVE; O75676; -.
DR   MaxQB; O75676; -.
DR   PaxDb; O75676; -.
DR   PeptideAtlas; O75676; -.
DR   PRIDE; O75676; -.
DR   ProteomicsDB; 50149; -. [O75676-1]
DR   ProteomicsDB; 50150; -. [O75676-2]
DR   Antibodypedia; 3272; 284 antibodies from 31 providers.
DR   DNASU; 8986; -.
DR   Ensembl; ENST00000334205.9; ENSP00000333896.4; ENSG00000162302.13. [O75676-1]
DR   GeneID; 8986; -.
DR   KEGG; hsa:8986; -.
DR   MANE-Select; ENST00000334205.9; ENSP00000333896.4; NM_003942.3; NP_003933.1.
DR   UCSC; uc001oae.4; human. [O75676-1]
DR   CTD; 8986; -.
DR   DisGeNET; 8986; -.
DR   GeneCards; RPS6KA4; -.
DR   HGNC; HGNC:10433; RPS6KA4.
DR   HPA; ENSG00000162302; Low tissue specificity.
DR   MIM; 603606; gene.
DR   neXtProt; NX_O75676; -.
DR   OpenTargets; ENSG00000162302; -.
DR   PharmGKB; PA34848; -.
DR   VEuPathDB; HostDB:ENSG00000162302; -.
DR   eggNOG; KOG0603; Eukaryota.
DR   GeneTree; ENSGT00940000161083; -.
DR   InParanoid; O75676; -.
DR   OMA; HDVHHDQ; -.
DR   PhylomeDB; O75676; -.
DR   TreeFam; TF313438; -.
DR   PathwayCommons; O75676; -.
DR   Reactome; R-HSA-437239; Recycling pathway of L1.
DR   SignaLink; O75676; -.
DR   SIGNOR; O75676; -.
DR   BioGRID-ORCS; 8986; 22 hits in 1113 CRISPR screens.
DR   ChiTaRS; RPS6KA4; human.
DR   GeneWiki; RPS6KA4; -.
DR   GenomeRNAi; 8986; -.
DR   Pharos; O75676; Tchem.
DR   PRO; PR:O75676; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; O75676; protein.
DR   Bgee; ENSG00000162302; Expressed in right hemisphere of cerebellum and 143 other tissues.
DR   ExpressionAtlas; O75676; baseline and differential.
DR   Genevisible; O75676; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0035175; F:histone kinase activity (H3-S10 specific); IMP:UniProtKB.
DR   GO; GO:0044022; F:histone kinase activity (H3-S28 specific); IMP:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004711; F:ribosomal protein S6 kinase activity; NAS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0070498; P:interleukin-1-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0001818; P:negative regulation of cytokine production; TAS:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0032793; P:positive regulation of CREB transcription factor activity; TAS:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; TAS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0043687; P:post-translational protein modification; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:UniProtKB.
DR   CDD; cd05614; STKc_MSK2_N; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR037714; MSK2_N_dom.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR016239; Ribosomal_S6_kinase_II.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 2.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000606; Ribsml_S6_kin_2; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 2.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 2.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 2.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Inflammatory response; Kinase;
KW   Magnesium; Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Serine/threonine-protein kinase;
KW   Stress response; Transferase.
FT   CHAIN           1..772
FT                   /note="Ribosomal protein S6 kinase alpha-4"
FT                   /id="PRO_0000086205"
FT   DOMAIN          33..301
FT                   /note="Protein kinase 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          302..371
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   DOMAIN          411..674
FT                   /note="Protein kinase 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          673..696
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          725..772
FT                   /note="Required for nuclear targeting and association with
FT                   MAPK14"
FT   REGION          728..772
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        161
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        530
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250"
FT   BINDING         39..47
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         65
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         417..425
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         440
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         196
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         343
FT                   /note="Phosphoserine; by MAPK1, MAPK3 and MAPK14"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         347
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163"
FT   MOD_RES         360
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         365
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         542
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         568
FT                   /note="Phosphothreonine; by MAPK1, MAPK3 and MAPK14"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         634
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         678
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         687
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163"
FT   MOD_RES         737
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         745
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:24275569"
FT   VAR_SEQ         401..406
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9687510, ECO:0000303|Ref.3"
FT                   /id="VSP_017733"
FT   VARIANT         236
FT                   /note="S -> L (in a breast infiltrating ductal carcinoma
FT                   sample; somatic mutation; dbSNP:rs746466314)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040632"
FT   VARIANT         758
FT                   /note="S -> A (in dbSNP:rs17857342)"
FT                   /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3"
FT                   /id="VAR_040633"
FT   MUTAGEN         709
FT                   /note="F->A: Strongly elevates basal activity."
FT                   /evidence="ECO:0000269|PubMed:11035004"
FT   CONFLICT        477
FT                   /note="L -> P (in Ref. 3; BAD97281)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        O75676-2:400..401
FT                   /note="QQ -> Q (in Ref. 3; BAD97281)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   772 AA;  85606 MW;  3606209693D0B5F3 CRC64;
     MGDEDDDESC AVELRITEAN LTGHEEKVSV ENFELLKVLG TGAYGKVFLV RKAGGHDAGK
     LYAMKVLRKA ALVQRAKTQE HTRTERSVLE LVRQAPFLVT LHYAFQTDAK LHLILDYVSG
     GEMFTHLYQR QYFKEAEVRV YGGEIVLALE HLHKLGIIYR DLKLENVLLD SEGHIVLTDF
     GLSKEFLTEE KERTFSFCGT IEYMAPEIIR SKTGHGKAVD WWSLGILLFE LLTGASPFTL
     EGERNTQAEV SRRILKCSPP FPPRIGPVAQ DLLQRLLCKD PKKRLGAGPQ GAQEVRNHPF
     FQGLDWVALA ARKIPAPFRP QIRSELDVGN FAEEFTRLEP VYSPPGSPPP GDPRIFQGYS
     FVAPSILFDH NNAVMTDGLE APGAGDRPGR AAVARSAMMQ DSPFFQQYEL DLREPALGQG
     SFSVCRRCRQ RQSGQEFAVK ILSRRLEANT QREVAALRLC QSHPNVVNLH EVHHDQLHTY
     LVLELLRGGE LLEHIRKKRH FSESEASQIL RSLVSAVSFM HEEAGVVHRD LKPENILYAD
     DTPGAPVKII DFGFARLRPQ SPGVPMQTPC FTLQYAAPEL LAQQGYDESC DLWSLGVILY
     MMLSGQVPFQ GASGQGGQSQ AAEIMCKIRE GRFSLDGEAW QGVSEEAKEL VRGLLTVDPA
     KRLKLEGLRG SSWLQDGSAR SSPPLRTPDV LESSGPAVRS GLNATFMAFN RGKREGFFLK
     SVENAPLAKR RKQKLRSATA SRRGSPAPAN PGRAPVASKG APRRANGPLP PS
//
